Antimicrobial resistance (AMR) is increasingly being recognised as a material economic risk, with the World Health Organization (WHO) projecting that it could add up to US$1 trillion in global healthcare costs by 2050. This issue will take centre stage at the AMR Leaders’ Summit from 12-13
